CIBC Private Wealth Group’s Galectin Therapeutics GALT Stock Holding History

CIBC Private Wealth Group’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$832	Buy	+200	New	+$1.05K	﹤0.01%	2954

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

CIBC Private Wealth Group's GALT Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Galectin Therapeutics (GALT) in Q4 2025: 200 shares worth $832. The stake represents ﹤0.01% of the portfolio and ranks #2954 among its holdings.

98 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

CIBC Private Wealth Group held 200 shares of Galectin Therapeutics worth $832 as of Q4 2025.
Galectin Therapeutics was a new CIBC Private Wealth Group position in Q4 2025.
Galectin Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2954 holding.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.